BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 28418195)

  • 1. Association between type 2 diabetes, curative treatment and survival in men with intermediate- and high-risk localized prostate cancer.
    Crawley D; Garmo H; Rudman S; Stattin P; Zethelius B; Holmberg L; Adolfsson J; Van Hemelrijck M
    BJU Int; 2018 Feb; 121(2):209-216. PubMed ID: 28418195
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment with curative intent and survival in men with high-risk prostate cancer. A population-based study of 11 380 men with serum PSA level 20-100 ng/mL.
    Ladjevardi S; Berglund A; Varenhorst E; Bratt O; Widmark A; Sandblom G
    BJU Int; 2013 Mar; 111(3):381-8. PubMed ID: 22758210
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Does a prostate cancer diagnosis affect management of pre-existing diabetes? Results from PCBaSe Sweden: a nationwide cohort study.
    Crawley D; Garmo H; Rudman S; Stattin P; Zethelius B; Armes J; Holmberg L; Adolfsson J; Van Hemelrijck M
    BMJ Open; 2018 Mar; 8(3):e020787. PubMed ID: 29549214
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metformin may offer no protective effect in men undergoing external beam radiation therapy for prostate cancer.
    Ranasinghe WKB; Williams S; Ischia J; Wetherell D; Baldwin G; Shulkes A; Sengupta S; Bolton D; Patel O
    BJU Int; 2019 May; 123 Suppl 5():36-42. PubMed ID: 31012989
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association between duration and type of androgen deprivation therapy and risk of diabetes in men with prostate cancer.
    Crawley D; Garmo H; Rudman S; Stattin P; Häggström C; Zethelius B; Holmberg L; Adolfsson J; Van Hemelrijck M
    Int J Cancer; 2016 Dec; 139(12):2698-2704. PubMed ID: 27557616
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mortality among men with locally advanced prostate cancer managed with noncurative intent: a nationwide study in PCBaSe Sweden.
    Akre O; Garmo H; Adolfsson J; Lambe M; Bratt O; Stattin P
    Eur Urol; 2011 Sep; 60(3):554-63. PubMed ID: 21664039
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of type 2 diabetes mellitus and antidiabetic medication with risk of prostate cancer: a population-based case-control study.
    Lin E; Garmo H; Van Hemelrijck M; Adolfsson J; Stattin P; Zethelius B; Crawley D
    BMC Cancer; 2020 Jun; 20(1):551. PubMed ID: 32539807
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of Radical Local Treatment with Mortality in Men with Very High-risk Prostate Cancer: A Semiecologic, Nationwide, Population-based Study.
    Stattin P; Sandin F; Thomsen FB; Garmo H; Robinson D; Lissbrant IF; Jonsson H; Bratt O
    Eur Urol; 2017 Jul; 72(1):125-134. PubMed ID: 27481175
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Active surveillance for localized prostate cancer: update of a prospective single-center cohort.
    Thostrup M; Thomsen FB; Iversen P; Brasso K
    Scand J Urol; 2018 Feb; 52(1):14-19. PubMed ID: 28958194
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Initial management of prostate-specific antigen-detected, low-risk prostate cancer and the risk of death from prostate cancer.
    Aizer AA; Chen MH; Hattangadi J; D'Amico AV
    BJU Int; 2014 Jan; 113(1):43-50. PubMed ID: 23473327
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term outcomes among noncuratively treated men according to prostate cancer risk category in a nationwide, population-based study.
    Rider JR; Sandin F; Andrén O; Wiklund P; Hugosson J; Stattin P
    Eur Urol; 2013 Jan; 63(1):88-96. PubMed ID: 22902040
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radical prostatectomy in Denmark: Survival analysis and temporal trends in clinicopathological parameters with up to 20 years of follow-up.
    Heering M; Berg KD; Brasso K; Iversen P; Røder MA
    Surg Oncol; 2017 Mar; 26(1):21-27. PubMed ID: 28317581
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcomes in localized prostate cancer: National Prostate Cancer Register of Sweden follow-up study.
    Stattin P; Holmberg E; Johansson JE; Holmberg L; Adolfsson J; Hugosson J;
    J Natl Cancer Inst; 2010 Jul; 102(13):950-8. PubMed ID: 20562373
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changes in treatment and mortality in men with locally advanced prostate cancer between 2000 and 2016: a nationwide, population-based study in Sweden.
    Orrason AW; Westerberg M; Garmo H; Lissbrant IF; Robinson D; Stattin P
    BJU Int; 2020 Jul; 126(1):142-151. PubMed ID: 32274889
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use and early mortality outcomes of active surveillance in patients with intermediate-risk prostate cancer.
    Butler SS; Mahal BA; Lamba N; Mossanen M; Martin NE; Mouw KW; Nguyen PL; Muralidhar V
    Cancer; 2019 Sep; 125(18):3164-3171. PubMed ID: 31150125
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differences according to socioeconomic status in the management and mortality in men with high risk prostate cancer.
    Berglund A; Garmo H; Robinson D; Tishelman C; Holmberg L; Bratt O; Adolfsson J; Stattin P; Lambe M
    Eur J Cancer; 2012 Jan; 48(1):75-84. PubMed ID: 21852113
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Competing-risks mortality after radiotherapy vs. observation for localized prostate cancer: a population-based study.
    Abdollah F; Sun M; Schmitges J; Thuret R; Tian Z; Shariat SF; Briganti A; Jeldres C; Perrotte P; Montorsi F; Karakiewicz PI
    Int J Radiat Oncol Biol Phys; 2012 Sep; 84(1):95-103. PubMed ID: 22330991
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neoadjuvant hormonal therapy use and the risk of death in men with prostate cancer treated with brachytherapy who have no or at least a single risk factor for coronary artery disease.
    Nanda A; Chen MH; Moran BJ; Braccioforte MH; Dosoretz D; Salenius S; Katin M; Ross R; D'Amico AV
    Eur Urol; 2014 Jan; 65(1):177-85. PubMed ID: 22981136
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advancing age within established Gleason score categories and the risk of prostate cancer-specific mortality (PCSM).
    Russo AL; Chen MH; Aizer AA; Hattangadi JA; D'Amico AV
    BJU Int; 2012 Oct; 110(7):973-9. PubMed ID: 22954029
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcomes of initially expectantly managed patients with low or intermediate risk screen-detected localized prostate cancer.
    Bul M; van den Bergh RC; Zhu X; Rannikko A; Vasarainen H; Bangma CH; Schröder FH; Roobol MJ
    BJU Int; 2012 Dec; 110(11):1672-7. PubMed ID: 22928973
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.